|
|
|
|
AAV titer and full capsid enrichment depend on tuning every process component, starting with the medium. Results across serotypes, reagents, and enhancers show how far a media-led approach can go.
|
|
|
|
|
New data show that a chemically defined, animal-origin-free media system significantly improves AAV2, AAV8, and AAV9 production. Uncover why medium selection is a foundational step in optimizing viral titer and full capsid yield.
|
|
|
|
|
Learn how optimized HEK293 cell culture media supports high cell density growth, viability, and productivity, enabling robust, scalable AAV production from early process development through commercial manufacturing.
|
|
|
|
|
This two-minute preview follows gene therapy from discovery and preclinical research through process development, manufacturing, regulatory engagement, and clinical trials. It highlights the bottlenecks between promising science and patients.
|
|
|
|
|
|
|
Accelerate your cell and gene therapy journey with integrated technologies, GMP expertise, and end-to-end solutions, from development through manufacturing, designed to help bring transformative therapies to patients faster.
|
|
|
